Wegovy Pill Just Changed the GLP-1 Market. Here's Why Eli Lilly Stock Could Still Win
2026-07-17 18:30
•Prosper Junior Bakiny •The Motley Fool
••• •• Axe Capital view
Wegovy Shakes Up GLP-1 Space But Eli Lilly Has Room to Run
Novo Nordisk’s oral Wegovy dominates the weight-loss pill market, yet Eli Lilly’s pipeline and label expansions keep it firmly in the race.
Novo Nordisk’s oral Wegovy quickly grabbed nearly 90% of the U.S. oral weight-loss pill prescriptions, a striking launch that’s expanded the overall market. That’s important because it’s not just taking business from rivals, but growing demand for GLP-1 drugs broadly. Eli Lilly lost some ground on the oral front but remains very relevant. Its Foundayo has less strict food rules, a subtle but meaningful advantage for patients. Plus, upcoming label expansions for conditions beyond weight loss could drive volume higher. This points to a longer game where Lilly’s broader clinical pipeline and new candidates like retatrutide—showing surgery-like results—might deliver fresh growth waves. South African investors won’t see a direct local play yet, but the USD/ZAR could track on broader pharma sentiment and U.S. dollar strength as capital flows follow biotech innovation. Buy Eli Lilly for exposure to a growing global obesity treatment market. If Wegovy continues to expand rapidly or Lilly stumbles with clinical setbacks, this view could be challenged. this is just my opinion and not financial advice
Buy Eli Lilly as a long-term growth play in obesity and diabetes treatments, while watching the USD/ZAR for biotech global shifts impacting funds flow.
- LLY
- USD/ZAR
- Wegovy’s market share expands further than expected
- Clinical setbacks or regulatory delays for Eli Lilly’s pipeline
6/10
Novo Nordisk's oral Wegovy launch has regained market share in the GLP-1 weight-loss drug market, capturing ~89% of oral weight-loss medication prescriptions in the U.S. However, Eli Lilly's Foundayo has potential advantages including fewer food restrictions and upcoming label expansions for multiple indications. Both companies remain well-positioned in the fast-growing anti-obesity market with strong pipelines.
This article was originally published by The Motley Fool and has been adapted here for Axe Capital Trading News.
Publisher: The Motley Fool
Author: Prosper Junior Bakiny
Categories: Equities, Earnings, Healthcare
Tickers: NVO, LLY
Sentiment: Positive - Oral Wegovy achieved one of the strongest pharmaceutical launches on record with 3+ million prescriptions by June, capturing ~89% of the oral weight-loss medication market. The drug is expanding the overall market rather than just cannibalizing existing products, demonstrating strong competitive momentum and market dominance. Despite losing oral market share to Wegovy, Eli Lilly maintains leadership in overall weight-loss drugs through Zepbound and has promising pipeline candidates like retatrutide with phase 3 results comparable to bariatric surgery. Foundayo has potential advantages and upcoming label expansions for multiple indications that could substantially boost prescription volume.
Keywords: GLP-1 drugs, weight-loss medications, oral formulations, pharmaceutical competition, clinical trials, market share, obesity treatment
Insights:
- NVO: Positive: Oral Wegovy achieved one of the strongest pharmaceutical launches on record with 3+ million prescriptions by June, capturing ~89% of the oral weight-loss medication market. The drug is expanding the overall market rather than just cannibalizing existing products, demonstrating strong competitive momentum and market dominance.
- LLY: Positive: Despite losing oral market share to Wegovy, Eli Lilly maintains leadership in overall weight-loss drugs through Zepbound and has promising pipeline candidates like retatrutide with phase 3 results comparable to bariatric surgery. Foundayo has potential advantages and upcoming label expansions for multiple indications that could substantially boost prescription volume.